Pooja Hingorani
Boston Children's Hospital
50 Papers
237 Citations
Pooja Hingorani is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Medicine & Osteosarcoma. The author has an hindex of 19, co-authored 43 publications.
Chat about Author
Papers
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.
TL;DR: Combinational immunotherapy approaches to block additional inhibitory pathways in patients with metastatic osteosarcoma may provide new strategies to enhance tumor clearance and resistance to disease.
Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Danielle M. Lussier,Lauren O’Neill,Lizbeth M. Nieves,Megan S. McAfee,Susan A. Holechek,Andrea W. Collins,Paul S. Dickman,Paul S. Dickman,Jeffrey Jacobsen,Pooja Hingorani,Joseph N. Blattman +10 more
TL;DR: Blockade of PD-1/PD-L1 interactions dramatically improves the function of osteosarcoma-reactive CTLs in vitro and in vivo, and results in decreased tumor burden and increased survival in the K7M2 mouse model of metastatic osteosARcoma.
187
Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
Darren Hargrave,Eric Bouffet,Uri Tabori,Alberto Broniscer,Kenneth J. Cohen,Jordan R. Hansford,Birgit Geoerger,Pooja Hingorani,Ira J. Dunkel,Mark W. Russo,Lillian Tseng,Kohinoor Dasgupta,Eduard Gasal,James A. Whitlock,Mark W. Kieran +14 more
TL;DR: Dabrafenib demonstrated meaningful clinical activity and acceptable tolerability in patients with BRAF V600–mutant pLGG, and the clinical activity, including objective response rates (ORRs) using Response Assessment in Neuro-Oncology criteria and safety across parts 1 and 2 are reported.
Incidence and Outcomes of Desmoplastic Small Round Cell Tumor: Results from the Surveillance, Epidemiology, and End Results Database
TL;DR: Although overall survival remains poor, radiation therapy following surgery seems to improve outcome in these patients, and DSRCT is more common in males and in people of African-American descent.
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation–Positive Solid Tumors
Mark W. Kieran,Birgit Geoerger,Ira J. Dunkel,Alberto Broniscer,Darren Hargrave,Pooja Hingorani,Isabelle Aerts,Anne Isabelle Bertozzi,Kenneth J. Cohen,Trent R. Hummel,Violet Shen,Eric Bouffet,Christine A. Pratilas,Andrew D.J. Pearson,Lillian Tseng,Noelia Nebot,Steven H. Green,Mark W. Russo,James A. Whitlock +18 more
TL;DR: In this first clinical trial in pediatric patients with pretreated BRAF V600–mutant tumors, dabrafenib was well tolerated while achieving target exposure levels; the average treatment duration was >1 year with many patients still on treatment.
88